Lung Cancer Medicare Access to Precise Testing Act

This bill requires Medicare to cover lung cancer biomarker testing for beneficiaries diagnosed with lung cancer, starting January 1, 2027. It defines the testing as procedures analyzing tissue, blood, or bodily fluids to identify specific biomarkers (like genes or proteins) for treatment planning. Medicare will pay 100% of reasonable charges for these tests, removing out-of-pocket costs for patients. The policy directly affects Medicare patients with lung cancer who need this specialized testing to guide personalized treatment options.